What is Oncoc4?
OncoC4 operates as a clinical-stage biotechnology enterprise dedicated to the discovery and development of novel biologics. The company maintains a robust pipeline that targets both validated and emerging pathways in oncology and immunological diseases. By focusing on first-in-class and best-in-class therapeutic candidates, OncoC4 distinguishes itself through a science-driven approach to drug discovery. Its market position is defined by its ability to bridge the gap between fundamental research and clinical application, aiming to deliver transformative treatments for patients suffering from complex, life-threatening conditions.
How much funding has Oncoc4 raised?
Oncoc4 has raised a total of $50M across 1 funding round:
Series B
$50M
Series B (2025): $50M with participation from Biosenomic gba investment fund, 3E Bioventures Capital, HM Capital Partners, and Kaitai Capital
Key Investors in Oncoc4
Biosenomic gba investment fund
Biosenomic gba is an investment fund management company led by director Michael Neubauer, focusing on providing investment opportunities and financial growth for its clients.
3E Bioventures Capital
3E Bioventures Capital is a venture capital fund focused on life sciences, investing in leading health innovators in the biotech and TechBio sectors.
Kaitai Capital
Kaitai Capital is a venture capital management firm focused on innovative investment management, with investment areas including life sciences, artificial intelligence, and digital industries.
What's next for Oncoc4?
With the successful closure of this major enterprise-level funding, OncoC4 is poised to scale its operational capabilities and advance its lead candidates through critical clinical milestones. The strategic allocation of these funds will likely prioritize the expansion of research and development infrastructure and the acceleration of patient enrollment in ongoing trials. As the company navigates the complexities of the regulatory landscape, the focus remains on validating its therapeutic platforms to secure long-term value for stakeholders. Future growth will be contingent upon the successful translation of its preclinical data into positive clinical outcomes, potentially setting the stage for future partnerships or commercialization efforts.
See full Oncoc4 company page
